Stockreport

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

argenx SE - American Depositary Shares  (ARGX) 
PDF Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the [Read more]